KR102535959B1 - 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 결정질 형태를 제조하는 방법 - Google Patents

5-아미노-2,3-디하이드로프탈라진-1,4-디온의 결정질 형태를 제조하는 방법 Download PDF

Info

Publication number
KR102535959B1
KR102535959B1 KR1020187026714A KR20187026714A KR102535959B1 KR 102535959 B1 KR102535959 B1 KR 102535959B1 KR 1020187026714 A KR1020187026714 A KR 1020187026714A KR 20187026714 A KR20187026714 A KR 20187026714A KR 102535959 B1 KR102535959 B1 KR 102535959B1
Authority
KR
South Korea
Prior art keywords
acid
luminol
crystalline form
sodium
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187026714A
Other languages
English (en)
Korean (ko)
Other versions
KR20180107278A (ko
Inventor
토마스 마틴
요세프 브로이
율리안 프라이스너
볼프강 브리쉬
베글러 요르그 폰
Original Assignee
메트리오팜 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메트리오팜 아게 filed Critical 메트리오팜 아게
Publication of KR20180107278A publication Critical patent/KR20180107278A/ko
Application granted granted Critical
Publication of KR102535959B1 publication Critical patent/KR102535959B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187026714A 2016-02-16 2017-02-15 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 결정질 형태를 제조하는 방법 Active KR102535959B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16000380 2016-02-16
EP16000380.2 2016-02-16
PCT/EP2017/000209 WO2017140422A1 (en) 2016-02-16 2017-02-15 Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

Publications (2)

Publication Number Publication Date
KR20180107278A KR20180107278A (ko) 2018-10-01
KR102535959B1 true KR102535959B1 (ko) 2023-05-23

Family

ID=55361317

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026714A Active KR102535959B1 (ko) 2016-02-16 2017-02-15 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 결정질 형태를 제조하는 방법

Country Status (8)

Country Link
US (1) US11203575B2 (enExample)
EP (1) EP3416952B1 (enExample)
JP (1) JP6949856B2 (enExample)
KR (1) KR102535959B1 (enExample)
CN (1) CN109071461B (enExample)
CA (1) CA3011766C (enExample)
ES (1) ES2796476T3 (enExample)
WO (1) WO2017140422A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3870175B1 (en) * 2018-10-26 2024-08-28 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
EP3858328A1 (en) * 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
PL4125802T3 (pl) * 2020-03-25 2026-03-23 Metriopharm Ag 5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc
AU2021288757B2 (en) * 2020-06-10 2026-01-08 Metriopharm Ag Compound for the treatment of coronaviral infections
KR20230116786A (ko) 2020-12-01 2023-08-04 리버스피에이에이치 엘엘씨 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물
US20240075029A1 (en) * 2020-12-02 2024-03-07 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
EP4460309B1 (en) * 2022-01-07 2026-08-19 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743541A (en) * 1985-07-17 1988-05-10 Mast Immunosystems, Inc. Luminescent substrate preparation and its use in specific binding assays
FR2839155B1 (fr) * 2002-04-25 2005-02-04 Roc Imp Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang
BRPI0307864B1 (pt) * 2003-11-25 2016-01-12 Univ Rio De Janeiro processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos
CN100390152C (zh) * 2006-03-23 2008-05-28 潘健 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
PT2542535E (pt) * 2010-03-01 2014-08-25 Metriopharm Ag Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
WO2011123776A2 (en) * 2010-04-01 2011-10-06 Guthery B Eugene Method for detecting occult blood
US20110246075A1 (en) * 2010-04-01 2011-10-06 Banik Niranjan C Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Thomas Martin 등, Crystral Growth & Design, 2016, 제16권, 페이지 3014-3018

Also Published As

Publication number Publication date
EP3416952B1 (en) 2020-04-08
EP3416952A1 (en) 2018-12-26
US20200369623A1 (en) 2020-11-26
JP6949856B2 (ja) 2021-10-13
JP2019504865A (ja) 2019-02-21
CA3011766C (en) 2023-08-01
CN109071461A (zh) 2018-12-21
CN109071461B (zh) 2022-06-21
US11203575B2 (en) 2021-12-21
CA3011766A1 (en) 2017-08-24
KR20180107278A (ko) 2018-10-01
ES2796476T3 (es) 2020-11-27
WO2017140422A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
KR102535960B1 (ko) 5-아미노-2,3-디하이드로프탈라진-1,4-디온의 새로운 결정질 형태
US11203575B2 (en) Methhod for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
EP3534904B1 (en) Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
WO2017202496A1 (en) Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the ligaments of the joints, articular capsules and bursae
JP7824925B2 (ja) グルココルチコイド節約剤
JP7807378B2 (ja) 稀な慢性炎症性肺疾患の治療における５－アミノ－２，３－ジヒドロ－１，４－フタラジンジオンの使用
CN116963738A (zh) 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺
HK40001510B (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001510A (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001511A (en) Crystalline form of 5-amino-2,3-dihydrophtalazine-1,4-dione

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4